menu
    • menu
    [{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","graph1":"Oncology","graph2":"Phase II","graph3":"Constellation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Constellation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constellation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","graph1":"Oncology","graph2":"Phase II","graph3":"Constellation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Constellation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constellation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pelabresib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Constellation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Constellation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constellation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"MorphoSys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Pelabresib","moa":"BET","graph1":"Oncology","graph2":"Phase III","graph3":"Constellation Pharmaceuticals","amount2":1.7,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Tablet","sponsorNew":"Constellation Pharmaceuticals \/ MorphoSys","highestDevelopmentStatusID":"10","companyTruncated":"Constellation Pharmaceuticals \/ MorphoSys"},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","graph1":"Oncology","graph2":"Phase III","graph3":"Constellation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Constellation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Constellation Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Pelabresib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":2.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":2.8999999999999999,"dosageForm":"Tablet","sponsorNew":"MorphoSys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pelabresib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Pelabresib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Novartis Pharmaceuticals Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals for Pelabresib

    Menu

    Pelabresib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MorphoSys

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novartis Meets All Tender Offer Conditions to Acquire MorphoSys for EUR 68 per Share

                            Details : Novartis will begin to progress the integration of MorphoSys, including full access to CPI-0610 (pelabresib), a novel BET inhibitor in combination with ruxolitinib for patients with myelofibrosis.

                            Brand Name : CPI-0610

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 16, 2024

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MorphoSys

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $2,897.9 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novartis Acquires MorphoSys AG To Strengthen Oncology Pipeline

                            Details : Novartis aims to enhance its oncology pipeline with CPI-0610 (pelabresib), a novel treatment for myelofibrosis with a favorable safety profile when combined with ruxolitinib.

                            Brand Name : CPI-0610

                            Molecule Type : Small molecule

                            Upfront Cash : $2,897.9 million

                            February 05, 2024

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $2,897.9 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MorphoSys

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement i...

                            Details : CPI-0610 (pelabresib monohydrate) is an investigational BET inhibitor. It is being developed in combination with the JAK inhibitor ruxolitinib for the treatment of myelofibrosis.

                            Brand Name : CPI-0610

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 20, 2023

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MorphoSys

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib i...

                            Details : Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain proteins to decrease the expression of abnormally expressed genes in cancer.

                            Brand Name : CPI-0610

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 10, 2022

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Constellation Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Constellation Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib

                            Details : Pelabresib durably reduced inflammatory cytokines such as tumor necrosis factor alpha (TNF alpha) and interleukin 18 (IL18) as early as 2 weeks and maintained through 24 weeks of treatment, based on an analysis of patient samples.

                            Brand Name : CPI-0610

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 11, 2021

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Constellation Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Constellation Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : MorphoSys

                            Deal Size : $1,700.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Morphosys to Buy Constellation in $1.7B Deal, Aided by Unusual Funding

                            Details : Constellation's lead product candidates, pelabresib (CPI-0610), a BET inhibitor, and CPI-0209, a 2nd-gen EZH2 inhibitor, are in mid- to late-stage clinical trials and have broad therapeutic potential to offer benefits to patients with various hematologic...

                            Brand Name : CPI-0610

                            Molecule Type : Small molecule

                            Upfront Cash : $1,700.0 million

                            June 02, 2021

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : MorphoSys

                            Deal Size : $1,700.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Constellation Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Constellation Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Trial for CPI-061...

                            Details : Event includes a review of the clinical and translational data from MANIFEST presented during ASH, including 24-week data from 50-60 first line and 90-100 second line myelofibrosis patients. MANIFEST is an open-label Phase 2 trial of CPI-0610 in patients...

                            Brand Name : CPI-0610

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 23, 2020

                            Lead Product(s) : Pelabresib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Constellation Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Constellation Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise

                            Details : 37 of 51 evaluable patients (73%) achieved a 35% reduction in spleen volume (SVR35) at 12 weeks and had a median spleen volume reduction of 51% after receiving Arm 3 (1L) – CPI-0610 + ruxolitinib.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 12, 2020

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Constellation Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Constellation Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts

                            Details : Evidence of clinical activity was seen both as monotherapy and in combination with ruxolitinib. If these preliminary data are confirmed in further testing, CPI-0610 could become part of a new standard of care in myelofibrosis.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 14, 2020

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth